The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Highlights
The global Peripheral T-cell lymphoma Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Peripheral T-cell lymphoma Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Peripheral T-cell lymphoma Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Peripheral T-cell lymphoma Therapy in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Peripheral T-cell lymphoma Therapy include Antengene, Genor BioPharma Co., Ltd., Hospira (Pfizer Inc.), Dizal Pharma, Bristol-Myers Squibb Company, Sigma-Tau Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc. and Celgene Corporation, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Peripheral T-cell lymphoma Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peripheral T-cell lymphoma Therapy.
The Peripheral T-cell lymphoma Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Peripheral T-cell lymphoma Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peripheral T-cell lymphoma Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
- Antengene
- Genor BioPharma Co., Ltd.
- Hospira (Pfizer Inc.)
- Dizal Pharma
- Bristol-Myers Squibb Company
- Sigma-Tau Pharmaceuticals, Inc.
- Pacira Pharmaceuticals, Inc.
- Spectrum Pharmaceuticals, Inc.
- Celgene Corporation
- Eisai Co., Ltd.
- Leadiant Biosciences
- Merck
- Genmab AS
- HUYABIO International
Segment by Type
- Chidamide
- Selinexor
- Other
Segment by Application
- Hospitals
- Clinics
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
- Latin America (Mexico, Brazil, Rest of Latin America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peripheral T-cell lymphoma Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Chidamide
1.2.3 Selinexor
1.2.4 Other
1.3 Market by Application
1.3.1 Global Peripheral T-cell lymphoma Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peripheral T-cell lymphoma Therapy Market Perspective (2018-2029)
2.2 Peripheral T-cell lymphoma Therapy Growth Trends by Region
2.2.1 Global Peripheral T-cell lymphoma Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Peripheral T-cell lymphoma Therapy Historic Market Size by Region (2018-2023)
2.2.3 Peripheral T-cell lymphoma Therapy Forecasted Market Size by Region (2024-2029)
2.3 Peripheral T-cell lymphoma Therapy Market Dynamics
2.3.1 Peripheral T-cell lymphoma Therapy Industry Trends
2.3.2 Peripheral T-cell lymphoma Therapy Market Drivers
2.3.3 Peripheral T-cell lymphoma Therapy Market Challenges
2.3.4 Peripheral T-cell lymphoma Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peripheral T-cell lymphoma Therapy Players by Revenue
3.1.1 Global Top Peripheral T-cell lymphoma Therapy Players by Revenue (2018-2023)
3.1.2 Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Peripheral T-cell lymphoma Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peripheral T-cell lymphoma Therapy Revenue
3.4 Global Peripheral T-cell lymphoma Therapy Market Concentration Ratio
3.4.1 Global Peripheral T-cell lymphoma Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peripheral T-cell lymphoma Therapy Revenue in 2022
3.5 Peripheral T-cell lymphoma Therapy Key Players Head office and Area Served
3.6 Key Players Peripheral T-cell lymphoma Therapy Product Solution and Service
3.7 Date of Enter into Peripheral T-cell lymphoma Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peripheral T-cell lymphoma Therapy Breakdown Data by Type
4.1 Global Peripheral T-cell lymphoma Therapy Historic Market Size by Type (2018-2023)
4.2 Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Type (2024-2029)
5 Peripheral T-cell lymphoma Therapy Breakdown Data by Application
5.1 Global Peripheral T-cell lymphoma Therapy Historic Market Size by Application (2018-2023)
5.2 Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Peripheral T-cell lymphoma Therapy Market Size (2018-2029)
6.2 North America Peripheral T-cell lymphoma Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Peripheral T-cell lymphoma Therapy Market Size by Country (2018-2023)
6.4 North America Peripheral T-cell lymphoma Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peripheral T-cell lymphoma Therapy Market Size (2018-2029)
7.2 Europe Peripheral T-cell lymphoma Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Peripheral T-cell lymphoma Therapy Market Size by Country (2018-2023)
7.4 Europe Peripheral T-cell lymphoma Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size (2018-2029)
8.2 Asia-Pacific Peripheral T-cell lymphoma Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peripheral T-cell lymphoma Therapy Market Size (2018-2029)
9.2 Latin America Peripheral T-cell lymphoma Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Peripheral T-cell lymphoma Therapy Market Size by Country (2018-2023)
9.4 Latin America Peripheral T-cell lymphoma Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size (2018-2029)
10.2 Middle East & Africa Peripheral T-cell lymphoma Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Antengene
11.1.1 Antengene Company Detail
11.1.2 Antengene Business Overview
11.1.3 Antengene Peripheral T-cell lymphoma Therapy Introduction
11.1.4 Antengene Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.1.5 Antengene Recent Development
11.2 Genor BioPharma Co., Ltd.
11.2.1 Genor BioPharma Co., Ltd. Company Detail
11.2.2 Genor BioPharma Co., Ltd. Business Overview
11.2.3 Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Introduction
11.2.4 Genor BioPharma Co., Ltd. Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.2.5 Genor BioPharma Co., Ltd. Recent Development
11.3 Hospira (Pfizer Inc.)
11.3.1 Hospira (Pfizer Inc.) Company Detail
11.3.2 Hospira (Pfizer Inc.) Business Overview
11.3.3 Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Introduction
11.3.4 Hospira (Pfizer Inc.) Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.3.5 Hospira (Pfizer Inc.) Recent Development
11.4 Dizal Pharma
11.4.1 Dizal Pharma Company Detail
11.4.2 Dizal Pharma Business Overview
11.4.3 Dizal Pharma Peripheral T-cell lymphoma Therapy Introduction
11.4.4 Dizal Pharma Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.4.5 Dizal Pharma Recent Development
11.5 Bristol-Myers Squibb Company
11.5.1 Bristol-Myers Squibb Company Company Detail
11.5.2 Bristol-Myers Squibb Company Business Overview
11.5.3 Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Introduction
11.5.4 Bristol-Myers Squibb Company Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.5.5 Bristol-Myers Squibb Company Recent Development
11.6 Sigma-Tau Pharmaceuticals, Inc.
11.6.1 Sigma-Tau Pharmaceuticals, Inc. Company Detail
11.6.2 Sigma-Tau Pharmaceuticals, Inc. Business Overview
11.6.3 Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Introduction
11.6.4 Sigma-Tau Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.6.5 Sigma-Tau Pharmaceuticals, Inc. Recent Development
11.7 Pacira Pharmaceuticals, Inc.
11.7.1 Pacira Pharmaceuticals, Inc. Company Detail
11.7.2 Pacira Pharmaceuticals, Inc. Business Overview
11.7.3 Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Introduction
11.7.4 Pacira Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.7.5 Pacira Pharmaceuticals, Inc. Recent Development
11.8 Spectrum Pharmaceuticals, Inc.
11.8.1 Spectrum Pharmaceuticals, Inc. Company Detail
11.8.2 Spectrum Pharmaceuticals, Inc. Business Overview
11.8.3 Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Introduction
11.8.4 Spectrum Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.8.5 Spectrum Pharmaceuticals, Inc. Recent Development
11.9 Celgene Corporation
11.9.1 Celgene Corporation Company Detail
11.9.2 Celgene Corporation Business Overview
11.9.3 Celgene Corporation Peripheral T-cell lymphoma Therapy Introduction
11.9.4 Celgene Corporation Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.9.5 Celgene Corporation Recent Development
11.10 Eisai Co., Ltd.
11.10.1 Eisai Co., Ltd. Company Detail
11.10.2 Eisai Co., Ltd. Business Overview
11.10.3 Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Introduction
11.10.4 Eisai Co., Ltd. Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.10.5 Eisai Co., Ltd. Recent Development
11.11 Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Detail
11.11.2 Leadiant Biosciences Business Overview
11.11.3 Leadiant Biosciences Peripheral T-cell lymphoma Therapy Introduction
11.11.4 Leadiant Biosciences Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.11.5 Leadiant Biosciences Recent Development
11.12 Merck
11.12.1 Merck Company Detail
11.12.2 Merck Business Overview
11.12.3 Merck Peripheral T-cell lymphoma Therapy Introduction
11.12.4 Merck Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.12.5 Merck Recent Development
11.13 Genmab AS
11.13.1 Genmab AS Company Detail
11.13.2 Genmab AS Business Overview
11.13.3 Genmab AS Peripheral T-cell lymphoma Therapy Introduction
11.13.4 Genmab AS Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.13.5 Genmab AS Recent Development
11.14 HUYABIO International
11.14.1 HUYABIO International Company Detail
11.14.2 HUYABIO International Business Overview
11.14.3 HUYABIO International Peripheral T-cell lymphoma Therapy Introduction
11.14.4 HUYABIO International Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023)
11.14.5 HUYABIO International Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Chidamide
Table 3. Key Players of Selinexor
Table 4. Key Players of Other
Table 5. Global Peripheral T-cell lymphoma Therapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Peripheral T-cell lymphoma Therapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Peripheral T-cell lymphoma Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Peripheral T-cell lymphoma Therapy Market Share by Region (2018-2023)
Table 9. Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Peripheral T-cell lymphoma Therapy Market Share by Region (2024-2029)
Table 11. Peripheral T-cell lymphoma Therapy Market Trends
Table 12. Peripheral T-cell lymphoma Therapy Market Drivers
Table 13. Peripheral T-cell lymphoma Therapy Market Challenges
Table 14. Peripheral T-cell lymphoma Therapy Market Restraints
Table 15. Global Peripheral T-cell lymphoma Therapy Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Peripheral T-cell lymphoma Therapy Market Share by Players (2018-2023)
Table 17. Global Top Peripheral T-cell lymphoma Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral T-cell lymphoma Therapy as of 2022)
Table 18. Ranking of Global Top Peripheral T-cell lymphoma Therapy Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Peripheral T-cell lymphoma Therapy Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Peripheral T-cell lymphoma Therapy Product Solution and Service
Table 22. Date of Enter into Peripheral T-cell lymphoma Therapy Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Peripheral T-cell lymphoma Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Type (2018-2023)
Table 26. Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Type (2024-2029)
Table 28. Global Peripheral T-cell lymphoma Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Application (2018-2023)
Table 30. Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Application (2024-2029)
Table 32. North America Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 33. North America Peripheral T-cell lymphoma Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Peripheral T-cell lymphoma Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 35. Europe Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. Europe Peripheral T-cell lymphoma Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Peripheral T-cell lymphoma Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 38. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 39. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size by Region (2024-2029) & (US$ Million)
Table 41. Latin America Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 42. Latin America Peripheral T-cell lymphoma Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Peripheral T-cell lymphoma Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 44. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 47. Antengene Company Detail
Table 48. Antengene Business Overview
Table 49. Antengene Peripheral T-cell lymphoma Therapy Product
Table 50. Antengene Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 51. Antengene Recent Development
Table 52. Genor BioPharma Co., Ltd. Company Detail
Table 53. Genor BioPharma Co., Ltd. Business Overview
Table 54. Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Product
Table 55. Genor BioPharma Co., Ltd. Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 56. Genor BioPharma Co., Ltd. Recent Development
Table 57. Hospira (Pfizer Inc.) Company Detail
Table 58. Hospira (Pfizer Inc.) Business Overview
Table 59. Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Product
Table 60. Hospira (Pfizer Inc.) Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 61. Hospira (Pfizer Inc.) Recent Development
Table 62. Dizal Pharma Company Detail
Table 63. Dizal Pharma Business Overview
Table 64. Dizal Pharma Peripheral T-cell lymphoma Therapy Product
Table 65. Dizal Pharma Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 66. Dizal Pharma Recent Development
Table 67. Bristol-Myers Squibb Company Company Detail
Table 68. Bristol-Myers Squibb Company Business Overview
Table 69. Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Product
Table 70. Bristol-Myers Squibb Company Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 71. Bristol-Myers Squibb Company Recent Development
Table 72. Sigma-Tau Pharmaceuticals, Inc. Company Detail
Table 73. Sigma-Tau Pharmaceuticals, Inc. Business Overview
Table 74. Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product
Table 75. Sigma-Tau Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 76. Sigma-Tau Pharmaceuticals, Inc. Recent Development
Table 77. Pacira Pharmaceuticals, Inc. Company Detail
Table 78. Pacira Pharmaceuticals, Inc. Business Overview
Table 79. Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product
Table 80. Pacira Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 81. Pacira Pharmaceuticals, Inc. Recent Development
Table 82. Spectrum Pharmaceuticals, Inc. Company Detail
Table 83. Spectrum Pharmaceuticals, Inc. Business Overview
Table 84. Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product
Table 85. Spectrum Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 86. Spectrum Pharmaceuticals, Inc. Recent Development
Table 87. Celgene Corporation Company Detail
Table 88. Celgene Corporation Business Overview
Table 89. Celgene Corporation Peripheral T-cell lymphoma Therapy Product
Table 90. Celgene Corporation Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 91. Celgene Corporation Recent Development
Table 92. Eisai Co., Ltd. Company Detail
Table 93. Eisai Co., Ltd. Business Overview
Table 94. Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Product
Table 95. Eisai Co., Ltd. Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 96. Eisai Co., Ltd. Recent Development
Table 97. Leadiant Biosciences Company Detail
Table 98. Leadiant Biosciences Business Overview
Table 99. Leadiant Biosciences Peripheral T-cell lymphoma Therapy Product
Table 100. Leadiant Biosciences Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 101. Leadiant Biosciences Recent Development
Table 102. Merck Company Detail
Table 103. Merck Business Overview
Table 104. Merck Peripheral T-cell lymphoma Therapy Product
Table 105. Merck Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 106. Merck Recent Development
Table 107. Genmab AS Company Detail
Table 108. Genmab AS Business Overview
Table 109. Genmab AS Peripheral T-cell lymphoma Therapy Product
Table 110. Genmab AS Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 111. Genmab AS Recent Development
Table 112. HUYABIO International Company Detail
Table 113. HUYABIO International Business Overview
Table 114. HUYABIO International Peripheral T-cell lymphoma Therapy Product
Table 115. HUYABIO International Revenue in Peripheral T-cell lymphoma Therapy Business (2018-2023) & (US$ Million)
Table 116. HUYABIO International Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peripheral T-cell lymphoma Therapy Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Peripheral T-cell lymphoma Therapy Market Share by Type: 2022 VS 2029
Figure 3. Chidamide Features
Figure 4. Selinexor Features
Figure 5. Other Features
Figure 6. Global Peripheral T-cell lymphoma Therapy Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Peripheral T-cell lymphoma Therapy Market Share by Application: 2022 VS 2029
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Peripheral T-cell lymphoma Therapy Report Years Considered
Figure 11. Global Peripheral T-cell lymphoma Therapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Peripheral T-cell lymphoma Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Peripheral T-cell lymphoma Therapy Market Share by Region: 2022 VS 2029
Figure 14. Global Peripheral T-cell lymphoma Therapy Market Share by Players in 2022
Figure 15. Global Top Peripheral T-cell lymphoma Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral T-cell lymphoma Therapy as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Peripheral T-cell lymphoma Therapy Revenue in 2022
Figure 17. North America Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Peripheral T-cell lymphoma Therapy Market Share by Country (2018-2029)
Figure 19. United States Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Canada Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Peripheral T-cell lymphoma Therapy Market Share by Country (2018-2029)
Figure 23. Germany Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. France Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. U.K. Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Italy Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Russia Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Nordic Countries Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Share by Region (2018-2029)
Figure 31. China Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Japan Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. South Korea Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Southeast Asia Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. India Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Australia Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Peripheral T-cell lymphoma Therapy Market Share by Country (2018-2029)
Figure 39. Mexico Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Brazil Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Share by Country (2018-2029)
Figure 43. Turkey Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Saudi Arabia Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Antengene Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 46. Genor BioPharma Co., Ltd. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 47. Hospira (Pfizer Inc.) Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 48. Dizal Pharma Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 49. Bristol-Myers Squibb Company Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 50. Sigma-Tau Pharmaceuticals, Inc. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 51. Pacira Pharmaceuticals, Inc. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 52. Spectrum Pharmaceuticals, Inc. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 53. Celgene Corporation Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 54. Eisai Co., Ltd. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 55. Leadiant Biosciences Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 56. Merck Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 57. Genmab AS Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 58. HUYABIO International Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2018-2023)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
